Just wrote to Hilda
Dear Hilda
I have been questioning the decision for Cochrane to produce an update of the Exercise review including a new protocol since the plan was announced. One of my arguments was that at the time Cochrane announced the plan for the update, NICE were already undertaking a review of all treatments for ME/CFS to find evidence to inform their new guideline (now published), so it would be a wasteful duplication of effort.
Today I read an article in the BMJ about gender treatments for young people (
https://www.bmj.com/content/380/bmj.p382) and noticed a paragraph about Cochrane’s decision not to produce a review because NICE had already done it. See quote below
“Cochrane, an international organisation that has built its reputation on delivering independent evidence reviews, has yet to publish a systematic review of gender treatments in minors. But The BMJ has learnt that in 2020 Cochrane accepted a proposal to review puberty blockers and that it worked with a team of researchers through 2021 in developing a protocol, but it ultimately rejected it after peer review. A spokesperson for Cochrane told The BMJ that its editors have to consider whether a review “would add value to the existing evidence base,” highlighting the work of the UK’s National Institute for Health and Care Excellence, which looked at puberty blockers and hormones for adolescents in 2021. “That review found the evidence to be inconclusive, and there have been no significant primary studies published since.”
I hope Cochrane will come to the same sensible conclusion about the Exercise review, and announce that soon. The existing Cochrane review is now well over two years out of date, and contradicts NICE’s review findings. This has caused confusion, and led to prominent people associated with Cochrane to accuse NICE of “a disastrous misapplication of GRADE” (
https://www.bmj.com/content/371/bmj.m4774/rr-7). I hope Cochrane will reconsider its decision not to withdraw it.
With best wishes
Caroline